ES2191763T3 - Inhibidor del desarrollo de dependencia/tolerancia a un agente analgesico narcotico. - Google Patents
Inhibidor del desarrollo de dependencia/tolerancia a un agente analgesico narcotico.Info
- Publication number
- ES2191763T3 ES2191763T3 ES96926004T ES96926004T ES2191763T3 ES 2191763 T3 ES2191763 T3 ES 2191763T3 ES 96926004 T ES96926004 T ES 96926004T ES 96926004 T ES96926004 T ES 96926004T ES 2191763 T3 ES2191763 T3 ES 2191763T3
- Authority
- ES
- Spain
- Prior art keywords
- dependency
- narcotic analgesic
- inhibitor
- analgesic agent
- development
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/402—1-aryl substituted, e.g. piretanide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Addiction (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
LA PRESENTE INVENCION SE REFIERE A UN MEDICAMENTO QUE INCLUYE COMO INGREDIENTE ACTIVO UN COMPUESTO REPRESENTADO POR LA SIGUIENTE FORMULA: R SUP,2} UE R SUP,1} REPRESENTA UN GRUPO PIRIDILO, UN GRUPO PIRIDILO SUSTITUIDO, GRUPO FENILO, O UN GRUPO FENILO SUSTITUIDO; Y R SUP,2} REPRESENTA EL GRUPO 2 STAR OPCIONALMENTE SUSTITUIDO, E INHIBE EL DESARROLLO DE DEPENDENCIA INDUCIDO POR UN ANALGESICO NARCOTICO Y/O INHIBE EL DESARROLLO DE TOLERANCIA A LA ACCION ANALGESICA INDUCIDA POR UN AGENTE ANALGESICO NARCOTICO.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP20076395 | 1995-08-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2191763T3 true ES2191763T3 (es) | 2003-09-16 |
Family
ID=16429771
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES96926004T Expired - Lifetime ES2191763T3 (es) | 1995-08-07 | 1996-08-06 | Inhibidor del desarrollo de dependencia/tolerancia a un agente analgesico narcotico. |
Country Status (13)
Country | Link |
---|---|
US (1) | US6107330A (es) |
EP (1) | EP0844241B1 (es) |
KR (1) | KR19990036248A (es) |
CN (1) | CN1085979C (es) |
AT (1) | ATE231491T1 (es) |
AU (1) | AU6631396A (es) |
CA (1) | CA2228813A1 (es) |
DE (1) | DE69625913T2 (es) |
DK (1) | DK0844241T3 (es) |
ES (1) | ES2191763T3 (es) |
NO (1) | NO315078B1 (es) |
TW (1) | TW457087B (es) |
WO (1) | WO1997006139A1 (es) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998014213A1 (fr) * | 1996-10-01 | 1998-04-09 | Daiichi Pharmaceutical Co., Ltd. | Stabilisateur de la membrane mitochondriale |
CN1264301A (zh) * | 1997-07-15 | 2000-08-23 | 第一制药株式会社 | 遗忘症的预防、治疗药 |
US6890951B2 (en) | 1998-08-05 | 2005-05-10 | Brookhaven Science Associates Llc | Treatment of addiction and addiction-related behavior |
US20040077709A1 (en) * | 1999-05-31 | 2004-04-22 | Daiichi Pharmaceutical Co., Ltd. | Neuronal death inhibitors |
US6423739B1 (en) | 2000-02-23 | 2002-07-23 | Daiichi Pharmaceutical Co., Ltd. | Method for aiding cerebral recovery following neurodegeneration |
US6348489B1 (en) | 2000-04-11 | 2002-02-19 | Daiichi Pharmaceutical Co., Ltd. | Method of treating traumatic brain injury and other neuronal disorders |
WO2002053153A1 (fr) * | 2000-12-28 | 2002-07-11 | Daiichi Pharmaceutical Co., Ltd. | Medicaments permettant de traiter et de prevenir une douleur neurologique |
US7250422B2 (en) | 2002-10-29 | 2007-07-31 | Sungkyunkwan University | Pharmaceutical composition containing berberine as effective ingredient for preventing and treating addiction or tolerance to morphine |
US20060241144A1 (en) * | 2005-04-20 | 2006-10-26 | Albert Cha | Method for treating apathy syndrome |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5198317A (en) * | 1975-02-21 | 1976-08-30 | 22 okisopirorijin 11 iruasetamidochushaekinoseizoho | |
US4212878A (en) * | 1978-01-26 | 1980-07-15 | The Upjohn Company | Phenylacetamide derivative analgesics |
IT1141287B (it) * | 1979-06-13 | 1986-10-01 | Nattermann A & Cie | Ammidi di acidi pirrolidin-(2)-on-(1)-ilalchil-carbossilici,procedimento per la loro preparazione e prodotti medicinali che le contengono |
US4490167A (en) * | 1979-08-06 | 1984-12-25 | Ciba-Geigy Corporation | Oxime derivatives of diphenyl ethers and their use in herbicidal compositions |
BE893276A (fr) * | 1981-06-01 | 1982-11-24 | Sandoz Sa | Nouvelle application therapeutique d'un derive de l'acetamide |
IL91451A0 (en) * | 1988-08-30 | 1990-04-29 | Bristol Myers Co | Pharmaceutical compositions comprising azapiron compounds and their use in the treatment of addiction |
US5468749A (en) * | 1988-08-30 | 1995-11-21 | Gawin; Frank H. | Method for treatment of substance addiction |
US5185329A (en) * | 1988-08-30 | 1993-02-09 | Bristol-Myers Squibb Company | Method for treatment of substance addiction |
JPH03163030A (ja) * | 1989-08-28 | 1991-07-15 | Arizona Technol Dev Corp | アヘン剤活性を選択的に強化し、アヘン剤耐性と依存性を軽減するための組成物と方法 |
US5220018A (en) * | 1991-04-10 | 1993-06-15 | Merck & Co., Inc. | Cholecystokinin antagonists |
IL101514A (en) * | 1991-04-10 | 1996-01-31 | Merck & Co Inc | History of benzodiazepines and anticoagulants containing cholecystokinin containing them |
JPH0517421A (ja) * | 1991-07-10 | 1993-01-26 | Yamanouchi Pharmaceut Co Ltd | N−置換アミド誘導体 |
US5461157A (en) * | 1992-06-19 | 1995-10-24 | Daiichi Pharmaceutical Co., Ltd. | Process for preparing pyrrolidinylacetamide derivatives |
CA2098663A1 (en) * | 1992-06-19 | 1993-12-20 | Shinji Kamihara | Process for preparing pyrrolidinylacetamide derivative |
-
1995
- 1995-08-06 US US09/000,236 patent/US6107330A/en not_active Expired - Fee Related
-
1996
- 1996-08-06 CA CA002228813A patent/CA2228813A1/en not_active Abandoned
- 1996-08-06 CN CN96197355A patent/CN1085979C/zh not_active Expired - Fee Related
- 1996-08-06 AU AU66313/96A patent/AU6631396A/en not_active Abandoned
- 1996-08-06 EP EP96926004A patent/EP0844241B1/en not_active Expired - Lifetime
- 1996-08-06 AT AT96926004T patent/ATE231491T1/de not_active IP Right Cessation
- 1996-08-06 TW TW085109475A patent/TW457087B/zh not_active IP Right Cessation
- 1996-08-06 DK DK96926004T patent/DK0844241T3/da active
- 1996-08-06 ES ES96926004T patent/ES2191763T3/es not_active Expired - Lifetime
- 1996-08-06 WO PCT/JP1996/002207 patent/WO1997006139A1/ja active IP Right Grant
- 1996-08-06 KR KR1019980700916A patent/KR19990036248A/ko active IP Right Grant
- 1996-08-06 DE DE69625913T patent/DE69625913T2/de not_active Expired - Fee Related
-
1998
- 1998-02-06 NO NO19980531A patent/NO315078B1/no unknown
Also Published As
Publication number | Publication date |
---|---|
EP0844241A1 (en) | 1998-05-27 |
ATE231491T1 (de) | 2003-02-15 |
CN1198738A (zh) | 1998-11-11 |
NO315078B1 (no) | 2003-07-07 |
US6107330A (en) | 2000-08-22 |
DK0844241T3 (da) | 2003-05-12 |
EP0844241A4 (en) | 1998-11-18 |
CN1085979C (zh) | 2002-06-05 |
DE69625913T2 (de) | 2003-11-27 |
NO980531L (no) | 1998-04-06 |
NO980531D0 (no) | 1998-02-06 |
WO1997006139A1 (fr) | 1997-02-20 |
TW457087B (en) | 2001-10-01 |
CA2228813A1 (en) | 1997-02-20 |
AU6631396A (en) | 1997-03-05 |
EP0844241B1 (en) | 2003-01-22 |
DE69625913D1 (de) | 2003-02-27 |
KR19990036248A (ko) | 1999-05-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
GR3032083T3 (en) | Immunosuppressant and antiallergic compounds, e.g. n-(3-oxohexanoyl) homoserine lactone | |
EP1312601A4 (en) | CARBOXYLENE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, AND MEDICAMENTS CONTAINING THEM AS AN ACTIVE SUBSTANCE | |
ES2179071T3 (es) | Agentes vasodilatadores perifericos que comprenden como principio activo derivados de la piperidina 4-amino n-acilada. | |
ECSP034564A (es) | Composicion pesticida | |
DK0652005T3 (da) | Fremgangsmåder til inhibering af endometriose | |
EP1314719A4 (en) | BENZOIC ACID DERIVATIVES AND MEDICAMENTS HAVING THE SAME AS ACTIVE INGREDIENT | |
ATE112764T1 (de) | Diphenylpiperazinderivat. | |
DK0659427T3 (da) | 2-Phenyl-3-azoylbenzothiophener til forøgelse af thrombomodulinekspression | |
DK0652002T3 (da) | Anvendelse af 2-phenyl-3-aroylebenzothiophener til fremstilling af et medikament til hæmning af brusknedbrydning | |
ES2191763T3 (es) | Inhibidor del desarrollo de dependencia/tolerancia a un agente analgesico narcotico. | |
AR003137A1 (es) | Una composicion farmaceutica para tratar la leucemia | |
ATE245447T1 (de) | Inhibitor von gehirnödemen | |
ES2093091T3 (es) | Derivado de glutation. | |
ES2148561T3 (es) | Prevencion y curacion de enfermedades alergicas de tipo i. | |
ATE274903T1 (de) | Antivirale mittel | |
MX9206930A (es) | Nuevos compuestos | |
EP0978277A4 (en) | ANTI-RHUMATISMAL AGENTS | |
GEP20032956B (en) | Miticide Composition | |
SE9502841D0 (sv) | Wood preservatives | |
ES2170380T3 (es) | Nuevos insecticidas y acaricidas de hidrazinacarboxilato. | |
DE69304011D1 (de) | N-Substituierte Carbonyloxyalkylpyrrol enthaltende insekticide, acarizide und molluskizide Mittel | |
AR015458A1 (es) | Compuestos de tetrahidrofurano, y composicion farmaceutica que lo contiene. | |
ATE158503T1 (de) | Aids-virus-infektion hemmende zusammensetzung | |
DE69528984T2 (de) | Hemmung der leukotrienbiosynthese mittels harnstoffderivaten | |
KR950023403A (ko) | 치은증식 억제제 조성물 |